Herbs for mental illness: Effectiveness and interaction with conventional medicines

Journal of Family Practice

Volumn 54, Issue 9, 2005, Pages 789-800

  Vermani, Monica ^a,b   Milosevic, Irena ^c   Smith, Fraser ^d   Katzman, Martin A ^a,e  

^a START Clinic for Mood and Anxiety Disorders   (Canada)

^b ADLER SCHOOL OF PROFESSIONAL PSYCHOLOGY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CANADIAN COLLEGE OF NATUROPATHIC MEDICINE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CORTICOSTEROID; DIGOXIN; EPHEDRA EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HALOPERIDOL; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAVA EXTRACT; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENOTHIAZINE DERIVATIVE; PRIMROSE OIL; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; UNINDEXED DRUG; WARFARIN; YOHIMBINE;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DELAYED HYPERSENSITIVITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; EPILEPSY; EUPHORIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEPATITIS; HUMAN; HYPERTENSION; HYPOMANIA; JAUNDICE; LIVER TOXICITY; MANIA; MENTAL DISEASE; META ANALYSIS; NAUSEA; PHOTODERMATOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SKIN ALLERGY; STROKE; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA;

ANXIETY DISORDERS; DEMENTIA; DEPRESSIVE DISORDER; HUMANS; MENTAL DISORDERS; PHYTOTHERAPY; PLANT PREPARATIONS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 24644480084     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States-prevalence, costs and patterns of use. N Engl J Med 1993; 328:246-252.
2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in Alternative Medicine Use in the United States, 1990-1997: Results of a Follow-up National Survey. JAMA 1998; 280:1569-1575.
3. Pies R. Adverse neuropsychiatric reactions to herbal and over-the counter "antidepressants." J Clin Psychiatry 2000; 61:815-820.
4. Knaudt PR, Connor KM, Weisler RH, Churchill LE, Davidson JRT. Alternative therapy use by psychiatric outpatients. J Nerv Ment Dis 1999; 187:692-695.
5. Mamtani R, Cimino A. A primer of complementary and alternative medicine and its relevance in the treatment of mental health problems. Psychiatr Quart 2002; 73:367-381.
6. Wharton R, Lewith G. Complementary medicine and the general practitioner. BMJ 1986; 292:1498-1500.
7. Scimone A, Scimone AA. Recommendation of herbal remedies by psychiatrists. J Orthomol Med 2001; 16:155-156.
8. Wong AHC, Smith M, Boon HS. Botanical medicine in psychiatry. Psychiatry Rounds 1999; 3(2):1-5.
9. Wong AHC, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998; 55:1033-1044.
10. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St. John's wort for depression: An overview and meta-analysis of randomized clinical trials. BMJ 1996; 313:253-258.
11. Linde K, Mulrow CD. St. John's wort for depression (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chinchester, UK: John Wiley & Sons, Ltd.
12. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression. JAMA 2001; 285:1978-1986.
13. Davidson JRT. Effect of Hypericum perforatum (St John's wort) in major depressive disorder. JAMA 2002; 287:1807-1814.
14. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11:98-104.
15. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35:35-98.
16. Ernst E. Second thoughts about safety of St John's wort. Lancet 1999; 354:2014-2016.
17. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann Intern Med 2002; 136:42-53.
18. Hall S, Wang Z, Huang S, et al. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74:525-535.
19. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355:547-548.
20. Gordon JB. SSRIs and St. John's wort: Possible toxicity? Am Fam Physician 1998; 57:950-953.
21. Johne A, Brockmoller J, Bauer S. Pharmacokinetic interaction of digoxin with an herbal extract from St. John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66:338-345.
22. Walter G, Rey JM, Harding M. Psychiatrists' experience and views regarding St. John's wort and 'alternative' treatments. Aust NZ J Psychiatry 2000; 34:992-996.
23. Newall C, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996.
24. O'Breasail AM, Argouarch S. Hypomania and St. John's wort. Can J Psychiatry 1998; 43:747.
25. Moses EL, Mallinger AG. St. John's wort: Three cases of possible mania induction. J Clin Psychopharmacol 2000; 20:115-117.
26. Gonzalez-Seijo JC, Ramos YM, Lastra I. Manic episode and ginseng: Report of a possible case. J Clin Psychopharmacol 1995; 15:447-448.
27. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999; 55:567-575.
28. Kieffer D, Pantuso T. Panax ginseng. Am Fam Physician 2003; 68:1539-1542.
29. Wiklund IK, Mattsson LA, Lindgren R, Limoni C. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic post-menopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res 1999; 19:89-99.
30. Cardinal BJ, Engels HJ. Ginseng does not enhance psychological well-being in healthy, young adults: results of a double-blind, placebo-controlled, randomized clinical trial. J Am Diet Assoc 2001; 101:655-660.
31. Attele AS, Wua JA, Yuan CS. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 1999; 58:1685-1693.
32. Stockley I. Drug Interactions: A Sourcebook of Adverse Interactions, Their Mechanisms, Clinical Importance, and Management. 3rd ed. Cambridge, England: Blackwell Scientific Press; 1994.
33. Mitra SK, Chakraborti A, Bhattacharya SK. Neuropharmacological studies on Panax ginseng. Indian J Exp Biol 1996; 34:41-47.
34. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54:692-693.
35. Siegel RK. Ginseng abuse syndrome. JAMA 1979; 241:1614-1615.
36. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol 2003; 188(5 Suppl):S56-S65.
37. Kleijnen J. Evening primrose oil. BMJ 1994; 309:824-825.
38. Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Controlled Clinical Trials 1996; 17:60-68.
39. Barber HJ. Evening primrose oil: A panacea? Pharm J 1988; 240:723-725.
40. Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003; 138:468-471.
41. Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective-a current review. Phytother Res 2003; 17:703-712.
42. Rados C. Ephedra ban: no shortage of reasons. FDA Consum 2004; 38:6-7.
43. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289:1537-1545.
44. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001; 2:199-211.
45. Ang-Lee M, Moss J, Yuan C. Herbal medicines and perioperative care. JAMA 2001; 286:208-216.
46. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995; 12:49-51.
47. Brinker F. Interactions of pharmaceutical and botanical medicines. J Naturopathic Med 1997; 7:14-20.
48. Jacobs KM, Hirsch KA. Psychiatric complications of ma-huang. Psychosomatics 2000; 41:58-62.
49. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000; 343:833-838.
50. Doyle H, Kargin M. Herbal stimulant containing ephedrine has also caused psychosis. BMJ 1996; 313:756.
51. Capwell RR. Ephedrine-induced mania from an herbal diet supplement. Am J Psychiatry 1995; 152:647.
52. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from piper methysticum forster (kava-kava). Pharmacopsychiat 1998; 31:187-192.
53. VoIz HP, Kieser M. Kava-kava extract WS 1490 verses placebo in anxiety disorders: A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiat 1997; 30:1-5.
54. Pittler MH, Ehret V. Kava extract for treating anxiety (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Chichester, UK: John Wiley & Sons, Ltd.
55. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20:84-90.
56. Jussofie A, Schmiz A, Himke C. Kava-pyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116:469-474.
57. Boonen G, Haberlein H. Influence of genuine kavapyrone enantiomers on the GABAA binding site. Planta Med 1998; 64:504-506.
58. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and resin: studies on GABA-A, GABA-B, and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992; 712:120-126.
59. Gleitz J, Beile A, Peters T. (±)-Kavain inhibits veratridine-activated voltage- dependent Nat-channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995; 34:1133-1138.
60. Magura El, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract ingredients, (+)-methysticin and (+/-)-kavain inhibit voltage-operated Nat-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 91:345-351.
61. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava kava and alprazolam. Annu Int Med 1996; 125:940-941.
62. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16:147-155.
63. Kraft M, Spahn TW, Wenzel J, et al. Fulminant liver failure after administration of the herbal antidepressant kava-kava. Dtsch Med Wochenschr 2001; 126:970-972.
64. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998; 23:1410-1414.
65. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. BMJ 2001; 322:7279.
66. Stickel F, Baumuller HM, Seitz K, et al. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39:62-67.
67. Blumenthal M, Busse W, Goldberg A, et al, eds. The Complete German Commission E Monographs-Therapeutic Guide to Herbal Medicines. Austin: American Botanical Council; Boston: Integrative Medicine Communications; 1998.
68. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 31:89-97.
69. Stevinson C, Ernst E. Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Medicine 2000; 1:91-99.
70. Andreatini R, Sartori V, Seabra M, Leite J. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002; 16:650-654.
71. Cropley M, Cave Z, Ellis J, Middleton R. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. Phytother Res 2002; 16:23-27.
72. Hadley S, Petry J. Valerian. Am Fam Physician 2003; 67:1755-1758.
73. Houghton P. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999; 51:505-512.
74. Miller K, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L: Behavioural and anticonvulsant properties. Physiother Res Int 1996; 10:145-151.
75. Capasso A, DeFeo V, DeSimon F, Sorrentino L. Pharmacological effects of aqueous extracts from Valeriana adscendens. Physiother Res Int 1996; 10:309-312.
76. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. American Herbal Products Association's Botanical Safety Handbook. Boca Raton, Fla: CRC Press; 1997.
77. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33:47-53.
78. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Pharmacopsychiatry 1999; 32:235-241.
79. Oken B, Storzbach D, Kaye J. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55:1409-1415.
80. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol 1992; 34:352-358.
81. Ernst E, Pittler M. Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 1999; 17:301-308.
82. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 1997; 278:1327-1332.
83. Oyama Y, Fuchs P, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res 1994; 635:125-129.
84. Cupp M, ed. Toxicology and Clinical Pharmacology of Herbal Products. Totowa, NJ: Humana Press; 2000.
85. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo. Neurol 1996; 46:1775-1776.
86. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336:1108.
87. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158:2200-2211.
88. Houghton P. Ginkgo. Pharm J 1994; 253:121-122.
89. Ernst E, Pittler M. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomized clinical trials. J Urol 1998; 159:433-436.
90. Morales A. Yohimbine in erectile dysfunction: The facts. Int J Impot Res 2000; Suppl 1:S70-S74.
91. Carey M, Johnson B. Effectiveness of yohimbine in the treatment of erectile disorder: Four meta-analytic integrations. Arch Sex Behav 1996; 25:341-360.
92. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: Biochemical and behavioural correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144:1030-1036.
93. Jordan J, Sharma A. Potential for sibutramine-yohimbine interaction? Lancet 2003; 361:1826.
94. Goldstein D, Grossman E, Listwak S, Folio C. Sympathetic reactivity during a yohimbine challenge test in essential hypertension. Hypertension 1991; 18 (Suppl 3):40-48.
95. Price L, Charney D, Heninger G. Three cases of manic symptoms following yohimbine administration. Am J Psychiatry 1984; 141:1267-1268.
96. Gear R, Gordon N, Heller P, Levine J. Enhancement of morphine analgesia by the alpha2-adrenergic antagonist yohimbine. Neuroscience 1995; 66:5-8.
97. McDougle C, Krystal J, Price L, Heninger G, Charney D. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine. Psychopharmacology (Berl) 1995; 118:127-135.
98. Rowland D, Tai W. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. J Sex Marital Ther 2003; 29:185-205.
99. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2000; 70:317-326.
100. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002; 30:1153-1157.
101. Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92:147-163.
102. Gardener D. Evidence-based decisions about herbal products for treating mental disorders. J Psychiatry Neurosci 2002; 27:324-333.